Eagle Pharmaceuticals to Host Second Quarter 2022 Financial Results on August 9, 2022
28 juil. 2022 16h05 HE
|
Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2022 second quarter...
Eagle Pharmaceuticals Appoints Debra M. Hussain as SVP, Head of Commercial
18 juil. 2022 06h50 HE
|
Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., July 18, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced the appointment of Debra M. Hussain as Senior Vice...
Eagle Pharmaceuticals Completes Acquisition of Acacia Pharma Group plc, Expanding Acute Care Footprint
09 juin 2022 07h30 HE
|
Eagle Pharmaceuticals, Inc.
Adds two U.S. Food and Drug Administration (“FDA”) approved new chemical entities with strong patent protectionBARHEMSYS® (amisulpride for injection) and BYFAVO® (remimazolam for injection) join Eagle...
Eagle Pharmaceuticals Announces Submission of New Drug Application to U.S. Food and Drug Administration for Landiolol, a Beta-1 Adrenergic Blocker
01 juin 2022 06h50 HE
|
Eagle Pharmaceuticals, Inc.
-- Submission seeks approval for landiolol for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter -- --...
Eagle Pharmaceuticals to Present at the William Blair 42nd Annual Growth Stock Conference
26 mai 2022 06h50 HE
|
Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., May 26, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle”) today announced that Scott Tarriff, President and Chief Executive Officer, and Brian...
Eagle Pharmaceuticals Reports First Quarter 2022 Results
09 mai 2022 06h50 HE
|
Eagle Pharmaceuticals, Inc.
Q1 2022 net income was $3.47 per basic and $3.41 per diluted share and adjusted non-GAAP net income* was $4.10 per basic and $4.04 per diluted shareQ1 2022 total revenue was $115.9 million, up from...
Eagle Pharmaceuticals to Host First Quarter 2022 Financial Results on May 9, 2022
28 avr. 2022 16h30 HE
|
Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., April 28, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2022 first quarter...
Eagle Pharmaceuticals Reaches Settlement Agreement with Hospira Related to BENDEKA® (bendamustine hydrochloride) until January 17, 2028
19 avr. 2022 06h50 HE
|
Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has reached a settlement agreement with...
Eagle Pharmaceuticals Agrees to Terms to Acquire Acacia Pharma Group plc
28 mars 2022 04h00 HE
|
Eagle Pharmaceuticals, Inc.
Expects to add two U.S. Food and Drug Administration (“FDA”)-approved, new chemical entities (“NCEs”) with patent life into 2031 and expand acute care footprintCommercialized assets, BARHEMSYS®...
Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results
07 mars 2022 06h50 HE
|
Eagle Pharmaceuticals, Inc.
Q4 2021 net loss was $(0.48) per basic and diluted share and adjusted non-GAAP net income* was $0.87 per basic and $0.85 per diluted shareFY 2021 net loss was $(0.66) per basic and diluted share and...